An embolic model of stroke in animals better approximates the dynamics of CBF changes, infarct progression, and maturation as it occurs in humans and also allows combination studies with intravenous tissue plasminogen activator (IV-tPA) [2, 3, 8], the only FDA approved reperfusion therapy. The gene discussed is PLAT; the disease is stroke disorder.